Get the Stockscreener App
72.10
0.28%
0.20
After Hours:
72.08
-0.02
-0.03%
Dexcom Inc stock is traded at $72.10, with a volume of 6.78M.
It is up +0.28% in the last 24 hours and up +13.70% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$71.90
Open:
$71.9
24h Volume:
6.78M
Relative Volume:
1.36
Market Cap:
$27.82B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
30.84
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
+16.99%
1M Performance:
+13.70%
6M Performance:
+19.71%
1Y Performance:
-15.01%
1-Day Range:
$71.31
$73.05
1-Week Range:
$61.54
$73.05
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.10 | 27.74B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Dexcom’s SWOT analysis: stock faces competitive headwinds in 2026 By Investing.com - Investing.com India
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings Signal Potential Upside - DirectorsTalk Interviews
Dexcom stock (US2521311074): earnings beat and fresh institutional interest keep CGM story in focus - AD HOC NEWS
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
DexCom Inc. stock outperforms competitors on strong trading day - MSN
How Dexcom Inc. (DXCM) Affects Rotational Strategy Timing - Stock Traders Daily
Does DexCom’s (DXCM) Flex Launch in Germany Hint at a Broader CGM Access Strategy Shift? - simplywall.st
Elliott strikes Dexcom board settlement after taking stake - MSN
6-Day Rally Sends DexCom Stock Up 25% - Trefis
Dexcom: A Medical Platform Play Gaining From AI, Not Disrupted By It (NYSEARCA:DEXC) - Seeking Alpha
DexCom Flex Launch Targets Wider Type 2 Market With Valuation Upside - Yahoo Finance
DexCom, Inc.Common Stock (NQ: DXCM - The Chronicle-Journal
Analysts Upgrade DexCom (DXCM) to “Outperform,” Driving Share Recovery - Insider Monkey
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom Stock Rockets 24% With 5-Day Winning Streak - Trefis
Dexcom stock (US2521311074): diabetes-tech player draws attention after Q1 earnings beat - AD HOC NEWS
DexCom Might Finally Be Cheap Enough (NASDAQ:DXCM) - Seeking Alpha
Here's why DexCom (DXCM) is a strong momentum stock - MSN
[144] DEXCOM INC SEC Filing - Stock Titan
Dexcom stock (US2521311074): Insider sale adds focus on shares - AD HOC NEWS
The DexCom Stock Turnaround Is Showing Real Signs of Life - Yahoo Finance
Here's Why DexCom (DXCM) is a Strong Momentum Stock - Yahoo Finance
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
Dexcom stock (US2521311074): Insider sale and sharp price jump put CGM specialist in focus - AD HOC NEWS
Dexcom (NASDAQ: DXCM) legal chief sells 1,700 shares under 10b5-1 plan - Stock Titan
Elliott to get two board seats at Dexcom ahead of investor day - MSN
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany - Zacks Investment Research
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $82 - Moomoo
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $85 - Moomoo
Devon Energy Corp stock (US2521311074): earnings momentum and oil price tailwinds in focus - AD HOC NEWS
A Look at DexCom Inc (DXCM) After 5.6% Gain -- GF Value $102.05 vs Price $65.09 - GuruFocus
Dexcom Inc. stock (US2521311074): buyback, 2030 targets and activist deal fire up DXCM - AD HOC NEWS
DexCom : Operations and Innovation Committee - marketscreener.com
DexCom Is Maintained at Buy by Canaccord Genuity - Moomoo
A Potential Turnaround Stock In Digital Healthcare - Good Money Guide
Here's why you should hold DexCom stock in your portfolio for now - MSN
DexCom (DXCM) Introduces Dexcom Flex for Type 2 Diabetes Patients - GuruFocus
DexCom Price Target Cut to $80.00/Share From $100.00 by B of A Securities - Moomoo
Dexcom stock (US2521311074): Analyst moves follow Elliott deal and new long-term targets - AD HOC NEWS
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany - 01net
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces - GuruFocus
DexCom Stock Jumps As 2030 Targets Ignite Bullish Trading - StocksToTrade
Dexcom Reveals Flex CGM for Type 2 Diabetes Patients - Medical Product Outsourcing
DexCom, Inc. Stock 12‑Month Price Target Cut to $82.28, Implies 34% Upside - TradingView
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo - Yahoo Finance
DexCom Expands CGM Access in Germany With New Dexcom Flex System for Type 2 Diabetes - Moomoo
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $82 - Moomoo
BofA Securities Adjusts Price Target on DexCom to $80 From $100 - marketscreener.com
DexCom Stock Jumps After Diabetes Management Firm Reaches Agreement With Elliott Investment Management - TIKR.com
DexCom, Inc. (DXCM) Stock Analysis: 33.77% Potential Upside Attracts Investor Attention - DirectorsTalk Interviews
Dexcom Inc. stock (US2521311074): diabetes tech player in focus after recent share move - AD HOC NEWS
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):